SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Jönsson Per Ebbe)
 

Search: WFRF:(Jönsson Per Ebbe) > 17 beta-Hydroxyster...

17 beta-Hydroxysteroid dehydrogenase type 1 as predictor of tamoxifen response in premenopausal breast cancer

Kallstrom, Ann-Christine (author)
Helsingborg Hospital
Salme, Rebecka (author)
Linköpings universitet,Institutionen för klinisk och experimentell medicin,Hälsouniversitetet
Rydén, Lisa (author)
Lund University,Lunds universitet,Kirurgi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Surgery (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine
show more...
Nordenskjöld, Bo (author)
Östergötlands Läns Landsting,Linköpings universitet,Onkologi,Hälsouniversitetet,Onkologiska kliniken US
Jönsson, Per-Ebbe (author)
Lund University,Lunds universitet,Kirurgi,Forskargrupper vid Lunds universitet,Surgery,Lund University Research Groups,Helsingborg Hospital
Stål, Olle (author)
Östergötlands Läns Landsting,Linköpings universitet,Onkologi,Hälsouniversitetet,Onkologiska kliniken US
show less...
 (creator_code:org_t)
Elsevier Science B.V., Amsterdam. 2010
2010
English.
In: EUROPEAN JOURNAL OF CANCER. - : Elsevier Science B.V., Amsterdam.. - 0959-8049 .- 1879-0852. ; 46:5, s. 892-900
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • 17 beta-Hydroxysteroid dehydrogenases (17HSDs) are involved in the local regulation of sex steroids. 17HSD1 converts oestrone (El) to the more potent oestradiol (E2) and 17HSD2 catalyses the reverse reaction. The aim of this study was to investigate the expression of these enzymes in premenopausal breast cancers and to analyse if they have any prognostic or tamoxifen predictive value. Premenopausal patients with invasive breast cancer, stage II (UICC), were randomised to either 2 years of adjuvant tamoxifen (n = 276) or no tamoxifen (n = 288). The median follow-up was 13.9 years (range 10.5-17.5). The expression of 17HSD1 and 17HSD2 was analysed with immunohistochemistry using tissue microarrays. The enzyme expression level (-/+/++/+++) was successfully determined in 396 and 373 tumours, respectively. Women with hormone-receptor positive tumours, with low levels (-/+/++) of 17HSD1, had a 43% reduced risk of recurrence, when treated with tamoxifen (Hazard Ratio (HR) = 0.57; 95% confidence interval (CI), 0.37-0.86; p = 0.0086). On the other hand high expression (+++) of 17HSD1 was associated with no significant difference between the two treatment arms (HR = 0.91; 95% CI, 0.43-1.95; p = 0.82). The interaction between 17HSD1 and tamoxifen was significant during the first 5 years of follow-up (p = 0.023). In the cohort of systemically untreated patients no prognostic importance was observed for 17HSD1. We found no predictive or prognostic value for 17HSD2. This is the first report of 17HSD1 in a cohort of premenopausal women with breast cancer randomised to tamoxifen. Our data suggest that 17HSD1 might be a predictive factor in this group of patients.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kirurgi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Surgery (hsv//eng)

Keyword

Breast cancer
17 beta-Hydroxysteroid dehydrogenases
HSD17B1
Tamoxifen
Predictive marker
Treatment prediction
Oestrogens
Premenopausal women
MEDICINE
MEDICIN
Premenopausal women
Oestrogens
Treatment prediction
Predictive marker
Tamoxifen
HSD17B1
Breast cancer
17 beta-Hydroxysteroid dehydrogenases

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view